Nan Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nan Zhou has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Lin-Feng Liu
Jiangxi University of Chinese Medicine, Nanchang, People’s Republic of China
1 shared publication Linfeng Liu
Jiangxi University of Traditional Chinese Medicine
1 shared publicationMingzhen He
Jiangxi University of Traditional Chinese Medicine
1 shared publication- Mingzhen He
Jiangxi University of Chinese Medicine, Nanchang, People’s Republic of China
1 shared publication Ran Wang
Jiangxi University of Traditional Chinese Medicine
1 shared publication- Ran Wang
Jiangxi University of Chinese Medicine, Nanchang, People’s Republic of China
1 shared publication
Latest Publications
- 19 December 2023
- Published by Springer Nature in Revista Brasileira de Farmacognosia
- Vol. 34 (3) , 492-500
Anti-asthmatic Substances in the Chinese Herbal Formulation Huagai San Based on In Vitro and In Vivo Analysis and Network Pharmacology
- 19 December 2023
- Published by Springer Nature in Revista Brasileira de Farmacognosia
- Vol. 34 (3) , 492-500
Anti-asthmatic Substances in the Chinese Herbal Formulation Huagai San Based on In Vitro and In Vivo Analysis and Network Pharmacology
- Open Access
- 7 June 2023
- Published by Springer Nature in Research Square
Study of potential anti-bronchial asthma substances in Huagai San based on in vitro and in vivo substance analysis and network pharmacology
Huagai San(HGS) is an herbal compound commonly used in the treatment of bronchial asthma. Although its effectiveness has been demonstrated in clinical applications, current research on HGS has focused on its clinical efficacy, with a lack of systematic material basis studies of the components. The mechanism of action and bioactive components of HGS are still unknown. In this study, we propose an integrated strategy based on in vivo and in vitro substance analysis and network pharmacology. The aim of this study is to elucidate the chemical composition, clarify the constituents absorbed in the blood, predict the main bioactive components, discovery of potential therapeutic targets, and use it in the study of potential anti-bronchial asthma substances for HGS. A four-step filtering strategy was established by using UHPLC-Q-TOF-MS/MS and applied to the identification of the chemical composition of HGS. 185 compounds were analyzed in the herbal components, and 65 compounds including 40 prototypes and 25 metabolic products were identified in rats. Based on the in vivo composition analysis of HGS, the bioactive components and potential therapeutic targets in the treatment of bronchial asthma were investigated by network pharmacological analysis. The results provide a scientific basis for understanding the bioactive components of HGS and their pharmacological mechanisms.
- 7 June 2023
- Published by Springer Nature in Research Square
Open AccessStudy of potential anti-bronchial asthma substances in Huagai San based on in vitro and in vivo substance analysis and network pharmacology
Huagai San(HGS) is an herbal compound commonly used in the treatment of bronchial asthma. Although its effectiveness has been demonstrated in clinical applications, current research on HGS has focused on its clinical efficacy, with a lack of systematic material basis studies of the components. The mechanism of action and bioactive components of HGS are still unknown. In this study, we propose an integrated strategy based on in vivo and in vitro substance analysis and network pharmacology. The aim of this study is to elucidate the chemical composition, clarify the constituents absorbed in the blood, predict the main bioactive components, discovery of potential therapeutic targets, and use it in the study of potential anti-bronchial asthma substances for HGS. A four-step filtering strategy was established by using UHPLC-Q-TOF-MS/MS and applied to the identification of the chemical composition of HGS. 185 compounds were analyzed in the herbal components, and 65 compounds including 40 prototypes and 25 metabolic products were identified in rats. Based on the in vivo composition analysis of HGS, the bioactive components and potential therapeutic targets in the treatment of bronchial asthma were investigated by network pharmacological analysis. The results provide a scientific basis for understanding the bioactive components of HGS and their pharmacological mechanisms.